Robin Kelley, MD
Internal Medicine · Los Angeles, CANPI 1700805223
Payments from drug & device makers
Across 425 payments — averaging $13,618 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.3M
- Genentech, Inc.$807K
- Servier Bioinnovation$556K
- AstraZeneca$458K
- Partner Therapeutics, Inc.$392K
- Exelixis Inc.$273K
- plus $996K from 21 others
Across 12 payments — averaging $1081.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$7K
- F. Hoffmann-la Roche AG$5K
- Servier Affaires Medicales$1K
- Taiho Oncology, Inc.$44
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 72 | $2,305,343 |
| Genentech, Inc. | 21 | $807,349 |
| Servier Bioinnovation | 75 | $556,296 |
| AstraZeneca | 35 | $458,043 |
| Partner Therapeutics, Inc. | 3 | $391,533 |
| Exelixis Inc. | 79 | $273,108 |
| Bayer | 3 | $194,789 |
| EMD Serono, Inc. | 44 | $146,319 |
| Eli Lilly | 6 | $134,244 |
| Taiho Oncology, Inc. | 9 | $128,160 |
| Agios Pharmaceuticals, Inc. | 31 | $125,836 |
| Bristol Myers Squibb | 2 | $87,961 |
| E.r. Squibb & Sons, L.L.C. | 9 | $57,275 |
| Novartis | 3 | $45,477 |
| QED Therapeutics, Inc. | 5 | $28,956 |
| Jazz Pharmaceuticals Inc. | 3 | $15,524 |
| Modernatx, Inc. | 2 | $4,898 |
| Servier Pharmaceuticals LLC | 4 | $4,502 |
| F. Hoffmann-la Roche AG | 4 | $4,124 |
| Incyte Corporation | 2 | $3,706 |
| Regeneron | 2 | $3,316 |
| GSK | 2 | $3,200 |
| Genmab U.S., Inc. | 1 | $3,200 |
| Astrazeneca UK Limited | 2 | $2,950 |
| Coherus Oncology, Inc. | 1 | $1,200 |
| Astrazeneca AB | 3 | $228 |
| Ipsen Innovation | 2 | $156 |
How this compares
$5,787,695 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.